27 related articles for article (PubMed ID: 301901)
1. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.
Brogden RN; Sorkin EM
Drugs; 1993 Oct; 46(4):652-77. PubMed ID: 7506651
[TBL] [Abstract][Full Text] [Related]
2. Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression.
Glazer RI
Cancer Chemother Pharmacol; 1980; 4(4):227-35. PubMed ID: 7002342
[No Abstract] [Full Text] [Related]
3. Animal model for immune dysfunction associated with adenosine deaminase deficiency.
Tedde A; Balis ME; Ikehara S; Pahwa R; Good RA; Trotta PP
Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4899-903. PubMed ID: 6968908
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of adenosine deaminase in the wasted mouse.
Abbott CM; Skidmore CJ; Searle AG; Peters J
Proc Natl Acad Sci U S A; 1986 Feb; 83(3):693-5. PubMed ID: 3456164
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and functional consequences of inhibiting adenosine deaminase during renal ischemia in rats.
Stromski ME; van Waarde A; Avison MJ; Thulin G; Gaudio KM; Kashgarian M; Shulman RG; Siegel NJ
J Clin Invest; 1988 Nov; 82(5):1694-9. PubMed ID: 3263396
[TBL] [Abstract][Full Text] [Related]
6. Purine metabolism in human lymphocytes.
Müller MM; Pischek G; Scheiner O; Stemberger H; Wiedermann G
Blut; 1979 Jun; 38(6):447-55. PubMed ID: 444683
[TBL] [Abstract][Full Text] [Related]
7. Combined immunodeficiency and inborn errors of purine metabolism.
Meuwissen HJ; Pollara B
Blut; 1978 Oct; 37(4):173-81. PubMed ID: 359065
[No Abstract] [Full Text] [Related]
8. Complete and partial adenosine deaminase deficiency. Relationship of immune function to metabolite concentrations, enzyme activity, and effects of therapy.
Hirschhorn R
Ann N Y Acad Sci; 1985; 451():20-5. PubMed ID: 3907453
[No Abstract] [Full Text] [Related]
9. Adenosine deaminase and malignant cells.
Balis ME
Ann N Y Acad Sci; 1985; 451():142-9. PubMed ID: 2866746
[No Abstract] [Full Text] [Related]
10. Studies of the relationship between adenosine deaminase and immune function.
Burridge PW; Paetkau V; Henderson JF
J Immunol; 1977 Aug; 119(2):675-8. PubMed ID: 301901
[TBL] [Abstract][Full Text] [Related]
11. Consequences of adenosine deaminase deficiency on thymocyte metabolism.
Thuillier L; Garreau F; Cartier PH
Eur J Immunol; 1981 Oct; 11(10):788-94. PubMed ID: 6975717
[TBL] [Abstract][Full Text] [Related]
12. The effects of an induced adenosine deaminase deficiency on T-cell differentiation in the rat.
Barton RW
Cell Immunol; 1985 Oct; 95(2):297-310. PubMed ID: 3876160
[TBL] [Abstract][Full Text] [Related]
13. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
Webster AD; Ip H; Pereira S
Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
[TBL] [Abstract][Full Text] [Related]
14. Adenosine deaminase inhibition for immunosuppression.
Chassin MM; Chirigos MA; Johns DG; Adamson RH
N Engl J Med; 1977 May; 296(21):1232. PubMed ID: 854065
[No Abstract] [Full Text] [Related]
15. Increased adenosine deaminase (ADA) activity and a shift from ADA-dependent to ADA-independent phases during T-cell activation: a paradox.
Veit BC; Fishman M; Look T
J Natl Cancer Inst; 1984 May; 72(5):1151-9. PubMed ID: 6609265
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
